NovaBridge Biosciences (NBP) Liabilities from Discontinued Operations (2023)
NovaBridge Biosciences (NBP) posted quarterly Liabilities from Discontinued Operations of 49669000.0 for Q4 2023.
NovaBridge Biosciences (NBP) Liabilities from Discontinued Operations (2023) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Liabilities from Discontinued Operations for 1 consecutive years, with 49669000.0 the latest figure, recorded in Q4 2023.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 49669000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 49669000.0 (changed N/A YoY) and the FY2023 annual result came in at 49669000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations held at 49669000.0 in Q4 2023 per NBP's latest filing.
- Over the last five years, Liabilities from Discontinued Operations for NBP reached as high as 49669000.0 in Q4 2023 and fell as low as 49669000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | NovaBridge Biosciences | 389.86 Mn | 389.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 49.67 Mn |
| Dec 31, 2023 | 49.67 Mn |